GLP-1 medications are no longer fringe – they’re mainstream, and they’re reshaping everything from public health to consumer behavior.
According to Kim Fisher, director of programs at the Innovation Institute for Food and Health (IIFH) at UC Davis, the scale of metabolic dysfunction in the US is staggering.